Galina S Bogatkevich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2966214/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases. Cellular and Molecular Immunology, 2021, 18, 1528-1544.	10.5	90
2	Differential DNA Methylation Landscape in Skin Fibroblasts from African Americans with Systemic Sclerosis. Genes, 2021, 12, 129.	2.4	12
3	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis and Rheumatology, 2019, 71, 2059-2067.	5.6	55
4	Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 115-124.	0.8	2
5	Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS ONE, 2017, 12, e0187580.	2.5	58
6	Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10. PLoS ONE, 2017, 12, e0188588.	2.5	6
7	D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts. PLoS ONE, 2016, 11, e0162357.	2.5	2
8	M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties inÂvitro and inÂvivo. Translational Research, 2016, 170, 99-111.	5.0	8
9	Editorial: Fate of Fat Tissue Adipocytes: Do They Transform Into Myofibroblasts in Scleroderma?. Arthritis and Rheumatology, 2015, 67, 860-861.	5.6	2
10	Recent Advances in Understanding the Pathogenesis of Scleroderma-Interstitial Lung Disease. Current Rheumatology Reports, 2014, 16, 411.	4.7	47
11	The PPAR <i>γ</i> Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Pulmonary Medicine, 2012, 2012, 1-9.	1.9	20
12	Coagulation and Autoimmunity in Scleroderma Interstitial Lung Disease. Seminars in Arthritis and Rheumatism, 2011, 41, 212-222.	3.4	25
13	Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis and Rheumatism, 2011, 63, 1416-1425.	6.7	100
14	The effects of bosentan on thrombinâ€activated fibroblasts and endothelial cells. FASEB Journal, 2010, 24, 774.3.	0.5	0
15	Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis and Rheumatism, 2009, 60, 3455-3464.	6.7	92
16	Dabigatran inhibits thrombin's differentiation of lung fibroblasts to a myofibroblast phenotype. FASEB Journal, 2009, 23, 1025.5.	0.5	1
17	Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L603-L611.	2.9	43
18	Proteomic analysis of connective tissue growth factor activation in normal and scleroderma lung fibroblasts. FASEB Journal, 2008, 22, 929.3.	0.5	0

#	Article	IF	CITATIONS
19	Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: Possible role in systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 2432-2442.	6.7	37
20	Downâ€regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. Arthritis and Rheumatism, 2007, 56, 3468-3477.	6.7	32
21	HGF reduces accumulation of collagen I in lung myofibroblasts isolated from Caucasian scleroderma patients via Grb2/Ras/MAPK/MMPâ€1â€dependant pathway. FASEB Journal, 2007, 21, A961.	0.5	0
22	Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L190-L201.	2.9	57
23	Contractile activity and smooth muscle α-actin organization in thrombin-induced human lung myofibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L334-L343.	2.9	55